Month: August 2020

SHANGHAI, China, Aug. 11, 2020 (GLOBE NEWSWIRE) — Bilibili Inc. (“Bilibili” or the “Company”) (NASDAQ: BILI), a leading online entertainment platform for young generations in China, today announced that it will report its second quarter 2020 unaudited financial results on Wednesday, August 26, 2020, after the close of U.S. markets.The Company’s management will host an earnings conference call at 9:00 PM U.S. Eastern Time on August 26, 2020 (9:00 AM Beijing/Hong Kong time on August 27, 2020). Details for the conference call are as follows:All participants must use the link provided above to complete the online registration process in advance of the conference call. Upon registering, each participant will receive a set of participant dial-in numbers, an event passcode, and a unique registrant ID, which will be used to join the conference...

CAMBRIDGE, Mass., Aug. 11, 2020 (GLOBE NEWSWIRE) — Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today reported financial results and corporate highlights for the second quarter 2020, as well as anticipated corporate milestones for the remainder of the year.“The second quarter of 2020 was one of great progress for Surface on several fronts. We advanced multiple programs in clinical development, entered into a clinical collaboration with Merck and secured additional financial resources via top-tier investors,” said Jeff Goater, chief executive officer. “Our team has done an amazing job adapting to challenges from the global COVID-19 pandemic. To date, our clinical and preclinical timelines have not been impacted by the pandemic...

Preliminary Data Demonstrates Normalization of CSF GBA1 Enzyme Activity in Parkinson’s Disease with GBA1 Mutations and Neuronopathic Gaucher Disease PatientsCompany Modifies Protocol for PROPEL Trial of PR001 for Parkinson’s Disease Patients with GBA1 Mutations; Expects to Continue Enrollment in Second Half of 2020PROVIDE Trial of PR001 for Type 2 Gaucher Disease and PROCLAIM Trial of PR006 for Frontotemporal Dementia Patients with GRN Mutations Expected to Initiate Enrollment in Second Half of 2020$75.0 Million At-The-Market Equity Program Conference call and live webcast today at 7:30 a.m. ETNEW YORK, Aug. 11, 2020 (GLOBE NEWSWIRE) — Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases, today reviewed recent...

CAMBRIDGE, Mass., Aug. 11, 2020 (GLOBE NEWSWIRE) — Generation Bio Co. (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of non-viral gene therapy, today reported recent business highlights and second quarter financial results.“The first half of 2020 has seen meaningful progress for Generation Bio, punctuated by the recent successful completion of our initial public offering,” said Geoff McDonough, M.D., president and chief executive officer of Generation Bio. “Our team continues to advance our science with efficiency, despite the uncertainties with the COVID-19 pandemic. Combined with our strong balance sheet, we are well-positioned to further develop our diverse portfolio for both rare and prevalent diseases.”Recent Business HighlightsAppointment of Matthew Norkunas, M.D., MBA as Chief Financial Officer: In...

CAMBRIDGE, Mass., and ROSTOCK and BERLIN, Aug. 11, 2020 (GLOBE NEWSWIRE) — Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies, announced today a release of CentoMD® 5.8  ̶  the latest update of the Company’s curated mutation database for rare diseases including epidemiologic, phenotypic, and clinical data. Since December 2019, the number of analyzed cases in CentoMD® has grown to more than 430,000, and the number of total unique variants increased to over 12.7 million, covering more than 120 countries.This latest update underlines the company’s continuous commitment to unlocking the deepest knowledge in rare diseases, such as disease-causing variants, precise genetic...

Continued progress in the AFM13 pTCL REDIRECT monotherapy studyAFM24 is recruiting patients in cohort 2 of a Phase 1/2a clinical trialGenentech’s RO7297089 is actively recruiting patients into a first-in-human Phase I trial resulting in the achievement of a milestone payment under the terms of the collaborationData on AFM24 and RO7297089 (formerly AFM26) were presented at the virtual AACR II conference in JuneAngus Smith joins the company as Chief Financial OfficerDr. Annalisa Jenkins and Harry Welten added to the Supervisory Board€92.6 million of cash, cash equivalents and current financial assets as of June 30, 2020, providing anticipated cash runway into the first half of 2022Conference call and webcast scheduled for August 11, 2020 at 8:30 am EDT (14:30 CET)Heidelberg, Germany, August 11, 2020 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage...